Results
|
|
1.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors:
Year: 2014
Citation: - Annals of Oncology. 25(6):1116-21, 2014 Jun.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM
|
|
|
2.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
Year: 2013
Citation: - Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
|
|
|
3.
|
Importance of gender in diffuse malignant peritoneal mesothelioma. MedStar authors:
Year: 2012
Citation: - Annals of Oncology. 23(6):1494-8, 2012 Jun.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Multicenter Study
All authors: - Cao C, Chua TC, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Peritoneal Surface Malignancy Group, Piso P, Sugarbaker PH, Yan TD
|
